Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is an interventional, non-randomized, controlled prospective study to treat HCV in
mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV
mono-infected controls. This pilot study will demonstrate whether functional cure of HCV
reduces myocardial injury and risk of cardiovascular disease.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
Merck Sharp & Dohme Corp. National Institutes of Health (NIH)
Treatments:
Elbasvir-grazoprevir drug combination Grazoprevir Ledipasvir Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir